EZH2 and Miyoshi myopathy: Hence, our data on characterization of the myeloma-associated expression of PLUM and its role in enhancing EZH2 stability and activity towards chemoresistance suggest its promising potential and future development as a biomarker and/or therapeutic target for MM.